Perioperative Chemoimmunotherapy Induces Strong Immune Responses and Long-Term Survival in Patients with HLA Class I-Deficient Non-Small Cell Lung Cancer

Baseline HLA class I tumor status (HLA-deficient or HLA-proficient) was determined by DNA loss of heterozygosity combined with immunohistochemistry for protein levels in tissue of 24 patients with NSCLC treated with perioperative nivolumab plus chemotherapy from NADIM trial.